Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
University of Connecticut
mi
from
Farmington, CT
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
University of Connecticut
mi
from
Farmington, CT
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic - Weston
mi
from
Weston, FL
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic - Weston
mi
from
Weston, FL
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Rutgers Cancer Institute of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Laura and Isaac Perlmutter Cancer Center @ NYU Langone
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Saint Luke's Roosevelt Hospital Center - Saint Luke's Division
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Mount Sinai Hosp
mi
from
New York, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Mount Sinai Hosp
mi
from
New York, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Montefiore Medical Center-Einstein Campus
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Montefiore Medical Center-Einstein Campus
mi
from
The Bronx, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Montefiore Medical Center-Weiler Hospital
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Montefiore Medical Center-Weiler Hospital
mi
from
The Bronx, NY
Click here to add this to my saved trials
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated:  10/4/2017
Eastchester Center for Cancer Care
mi
from
The Bronx, NY
Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer
A Randomized Phase II Study of Fulvestrant vs. Fulvestrant in Combination With Bortezomib in Women With ER Positive Metastatic Breast Cancer
Status: Enrolling
Updated: 10/4/2017
Eastchester Center for Cancer Care
mi
from
The Bronx, NY
Click here to add this to my saved trials
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)
Status: Enrolling
Updated:  10/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection
Pancreatic and Gastrointestinal Tumor Registry and Tissue Collection (UAB/UMN SPORE in Pancreatic Cancer)
Status: Enrolling
Updated: 10/4/2017
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Cedars-Siani Medical Center, Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Cedars-Siani Medical Center, Samuel Oschin Comprehensive Cancer Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Kaiser Permanente Oncology Hematology Clinic
mi
from
Denver, CO
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Kaiser Permanente Oncology Hematology Clinic
mi
from
Denver, CO
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
North Central Cancer Treatment Group, Illinois Cancer Care
mi
from
Peoria, IL
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
North Central Cancer Treatment Group, Illinois Cancer Care
mi
from
Peoria, IL
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
IU Simon Cancer Center
mi
from
Indianapolis, IN
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
IU Simon Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Weinberg Cancer Institute at Franklin Hospital
mi
from
Baltimore, MD
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Weinberg Cancer Institute at Franklin Hospital
mi
from
Baltimore, MD
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Clinical Research Alliance, Inc.
mi
from
Lake Success, NY
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
University of Cincinnati
mi
from
Cincinnati, OH
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
The Cleveland Clinic, Taussig Cancer Institute
mi
from
Cleveland, OH
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, Division of Hematology / Oncology
mi
from
Pittsburgh, PA
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
UPMC Cancer Pavilion, University of Pittsburgh Cancer Institute, Division of Hematology / Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Vanderbilt-Ingram Cancer Center
mi
from
Nashville, TN
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
South Texas Oncology & Hematology, P.A., The Start Center For Cancer Care
mi
from
San Antonio, TX
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
South Texas Oncology & Hematology, P.A., The Start Center For Cancer Care
mi
from
San Antonio, TX
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Seattle Cancer Care Alliance
mi
from
Seattle, WA
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
MD Anderson Cancer Center
mi
from
Orlando, FL
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
MD Anderson Cancer Center
mi
from
Orlando, FL
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
University of Chicago Medicine
mi
from
Chicago, IL
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
University of Chicago Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Karmanos Cancer Institute
mi
from
Detroit, MI
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Hôpital Saint André
mi
from
Bordeaux,
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Hôpital Saint André
mi
from
Bordeaux,
Click here to add this to my saved trials
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated:  10/4/2017
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
mi
from
Washington, D.C.,
IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma
A Randomized, Controlled Phase III Study Investigating IMA901 Multipeptide Cancer Vaccine in Patients Receiving Sunitinib as First-line Therapy for Advanced/Metastatic Renal Cell Carcinoma
Status: Enrolling
Updated: 10/4/2017
Georgetown University Medical Center, Lombardi Comprehensive Cancer Center
mi
from
Washington, D.C.,
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Clinical Research Facility
mi
from
New Haven, CT
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Clinical Research Facility
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Clinical Research Facility
mi
from
Detroit, MI
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Clinical Research Facility
mi
from
Portland, OR
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Clinical Research Facility
mi
from
Nashville, TN
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Clinical Research Facility
mi
from
Houston, TX
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated:  10/4/2017
Research Site
mi
from
The Bronx, NY
A Phase 1 Multicenter Open-label Study to Evaluate the Safety Tolerability and PK of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0680 (AMP-514) in Subjects With Advanced Malignancies
Status: Enrolling
Updated: 10/4/2017
Research Site
mi
from
The Bronx, NY
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
University of Florida Shands Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Mount Sinai Medical Center CCOP
mi
from
Miami Beach, FL
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Lucille P. Markey Cancer Center at University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Northern Rockies Radiation Oncology Center
mi
from
Billings, MT
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Methodist Estabrook Cancer Center
mi
from
Omaha, NE
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
McDowell Cancer Center at Akron General Medical Center
mi
from
Akron, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
McDowell Cancer Center at Akron General Medical Center
mi
from
Akron, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Jean and Milton Cooper Cancer Center at Summa Akron City Hospital
mi
from
Akron, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Charles M. Barrett Cancer Center at University Hospital
mi
from
Cincinnati, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford
mi
from
Salem, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Cancer Research UK Medical Oncology Unit at Churchill Hospital & Weatherall Institute of Molecular Medicine - Oxford
mi
from
Salem, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
Cancer Treatment Center
mi
from
Wooster, OH
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
Cancer Treatment Center
mi
from
Wooster, OH
Click here to add this to my saved trials
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated:  10/4/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
G-CSF and Pegfilgrastim in Treating Neutropenia in Patients Undergoing Radiation Therapy and Chemotherapy for Limited Stage Small Cell Lung Cancer
A Phase II Trial of Combined Modality Therapy With Growth Factor Support for Patients With Limited Stage Small Cell Lung Cancer
Status: Enrolling
Updated: 10/4/2017
McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
mi
from
Reading, PA
Click here to add this to my saved trials